or Try an Advanced Search...

    Fibroblast Growth Factor Receptor Stocks List

    Symbol Grade Name % Change
    BPMC A Blueprint Medicines Corporation 15.48
    BBIO D BridgeBio Pharma, Inc. 2.40
    FUSN A Fusion Pharmaceuticals Inc. 0.21
    NGM D NGM Biopharmaceuticals, Inc. 0.00
    RLAY D Relay Therapeutics, Inc. 5.41
    TYRA B Tyra Biosciences, Inc. 0.22
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Tyrosine Kinase Receptors Fibroblast Growth Factor Cell Biology Tyrosine Kinase Biopharmaceutical Bladder Cancer Cancer Clinical Development Insulin Precision Medicine Protein Kinase Inhibitor Solid Tumors Tumor Achondroplasia Advanced Solid Tumors Age Related Macular Degeneration Alcohol Amyloid Amyloidosis Antibodies

    Related ETFs - A few ETFs which own one or more of the above listed Fibroblast Growth Factor Receptor stocks.

    Symbol Grade Name Weight
    WDNA D WisdomTree BioRevolution Fund 4.03
    CNCR C Loncar Cancer Immunotherapy ETF 3.84
    BBP C BioShares Biotechnology Products Fund 3.71
    PBE C PowerShares Dynamic Biotech & Genome 2.89
    BTEC C Principal Healthcare Innovators Index ETF 2.74
    View all Fibroblast Growth Factor Receptor ETFs...
    Compare ETFs
    Compare CNCR to BBP Compare CNCR to BTEC Compare PBE to BTEC

        Fibroblast Growth Factor Receptor Stocks Recent News

        Date Stock Title
        May 2 FUSN Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
        May 2 BBIO BridgeBio Pharma GAAP EPS of -$0.20 beats by $0.31, revenue of $211.12M beats by $127.34M
        May 2 BBIO BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
        May 2 BPMC Blueprint Medicines  GAAP EPS of $1.40 beats by $3.05, revenue of $96.12M beats by $14.68M
        May 2 BBIO BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
        May 2 BPMC Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
        May 2 BBIO BridgeBio spinout launches with $200M for KRAS cancer drugs
        May 1 BPMC Blueprint Medicines Q1 2024 Earnings Preview
        May 1 BBIO Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
        Apr 30 BPMC Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
        Apr 26 FUSN Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
        Apr 26 FUSN Top 4 Health Care Stocks That May Plunge This Month
        Apr 26 BPMC The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
        Apr 25 FUSN Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
        Apr 25 RLAY Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
        Related Industries: Biotechnology
        Related Stock Lists: Tyrosine Kinase Receptors Fibroblast Growth Factor Cell Biology Tyrosine Kinase Biopharmaceutical Bladder Cancer Cancer Clinical Development Insulin Precision Medicine Protein Kinase Inhibitor Solid Tumors Tumor Achondroplasia Advanced Solid Tumors Age Related Macular Degeneration Alcohol Amyloid Amyloidosis Antibodies
        Fibroblast Growth Factor Receptor

        Fibroblast Growth Factor Receptor (FGFR) is a family of cell surface receptors that bind to and respond to fibroblast growth factors (FGFs). FGFRs are involved in a variety of cellular processes, including cell proliferation, differentiation, migration, and survival. They are also involved in the development of many diseases, including cancer.

        Browse All Tags